当归四逆加吴茱萸生姜汤对韩国手部冷过敏患者的疗效与安全性:一项初步、双盲、随机、安慰剂对照、平行组临床试验的研究方案
本研究为一项初步、多中心、双盲、随机、平行组、两臂、安慰剂对照临床试验,计划纳入66名韩国手部冷过敏女性,按1:1随机分为当归四逆加吴茱萸生姜汤组与安慰剂组,每日服药三次、共6周,以视觉模拟量表评分为主要结局,评估开展完整随机临床试验的可行性。
要点
- 手部冷过敏在韩国女性中常见,传统韩医药治疗有效性尚未经系统研究证实。
- 本研究为初步、多中心、双盲、随机、安慰剂对照、平行组、两臂临床试验,计划纳入66名参与者。
- 主要结局为手部冷过敏的视觉模拟量表评分,次要结局包括手部皮肤温度、临床总体印象量表评分等。
核心结论
- 本试验将是首个反映由韩医学专家共识新定义的手部冷过敏疾病范围的试验,将为后续大规模试验和韩国医学领域手部冷过敏的一般临床指南提供相当证据。
研究设计与样本
- 本研究为初步、多中心、双盲、随机、平行组、两臂、安慰剂对照临床试验,计划共纳入66名参与者,按1:1比例使用网络随机化系统分为当归四逆加吴茱萸生姜汤治疗组和安慰剂对照组。
主要发现
- 每组将每日服用当归四逆加吴茱萸生姜汤或安慰剂三次,持续6周。
- 主要结局将使用手部冷过敏的视觉模拟量表评分测量。
- 次要结局将包括手部皮肤温度变化、临床总体印象量表评分、冷应激试验后手部皮肤温度恢复率以及韩国版世界卫生组织生活质量量表简表。
- 本试验将是首个反映由韩医学专家共识新定义的手部冷过敏疾病范围的试验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, cold hypersensitivity in the hands (CHH) has become a common ailment of women in Korea. It can lead to gynecological problems such as irregular menstruation, miscarriage, and infertility. Traditionally, Korean herbal medicine has been the primary treatment method used to balance thermoregulation in the human body; however, its effectiveness has not been confirmed through systematic study. Thus, in this trial, we will investigate the feasibility of a full randomized clinical trial, Danggui-Sayuk-Ga-Osuyu-Saenggang-tang (DSGOST) in Korean women with CHH. METHODS: This study will be a pilot, multicenter, double-blind, randomized, parallel-group, two-arm, placebo-controlled clinical trial. A total of 66 participants will be randomly divided into two groups, a DSGOST treatment group and a placebo control group, in a 1:1 ratio using a web-based randomization system. Each group will take DSGOST or placebo three times daily for 6 weeks. The primary outcome will be measured using Visual Analogue Scale (VAS) scores of CHH. Secondary outcomes will include changes in skin temperature of the hands, Clinical Global Impressions (CGI) scale scores, recovery rate of skin temperature of the hands after the cold stress test, and the Korean version of the WHO Quality of Life Scale, abbreviated version (WHOQOL-BREF). DISCUSSION: This trial will be the first trial to reflect the newly defined disease range of CHH which was compiled by Korean medicine expert consensus. This study will provide considerable evidence for further large-scale trials and general clinical guidelines for CHH in the Korean medical field. TRIAL REGISTRATION: This study is registered at ClinicalTrials.gov, ID: NCT02645916 . Registered on 30 December 2015.
引用
- Ko Y, Go HY, Cho YY, et al. The efficacy and safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean patients with cold hypersensitivity in the hands: study protocol for a pilot, double-blind, randomized, placebo-controlled, parallel-group clinical trial. Trials. 2017. PMID: 28595610. doi:10.1186/s13063-017-2002-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。